Publications by authors named "Fabrizio Marino"
Brentuximab vedotin (BV) plus doxorubicin, vinblastine and dacarbazine (AVD) demonstrated to improve survival compared to ABVD as frontline treatment of advanced stage Hodgkin Lymphoma (HL). We retrospectively collected data of 99 stage IV HL patients treated off-protocol with BV-AVD to evaluate the predictive role of interim-PET. Median age was 36 years (range: 18-82); 83.
View Article and Find Full Text PDFMarginal zone lymphoma (MZL) is the most common indolent lymphoma primarily arising in the central nervous system (CNS). To date, 207 cases of primary CNS MZL (PCNSMZL) were published, mostly as single case reports or small case series. It most commonly presents as extra-axial dural-based masses, more frequently in middle-aged women, displaying an insidious onset, with a long history of symptoms preceding the diagnosis.
View Article and Find Full Text PDFReliable biomarkers for early identification of treatment failure in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL) are lacking. Circulating tumour DNA (ctDNA) profiling has emerged as a powerful predictive and prognostic tool in several haemopoietic and non-haemopoietic malignancies and may guide rational treatment choices in r/r cHL. To assess the predictive and prognostic value of ctDNA, we performed a retrospective analysis on 55 r/r cHL patients treated with the bendamustine, gemcitabine and vinorelbine (BEGEV) regimen and additionally evaluated the potential utility of integrating ctDNA with interim [ F]-FDG positron emission tomography (iPET).
View Article and Find Full Text PDFArticle Synopsis
- - DLBCL is a complex lymphoma type that includes several subtypes, such as double expressor lymphomas (DEL) and double/triple-hit lymphomas (DH/TH), with notable genetic features like MYC and BCL2 overexpression and TP53 mutations.
- - A study involving 122 patients treated with dose-adjusted EPOCH and rituximab (DA-EPOCH-R) showed promising results, with 2-year progression-free survival at 74% and overall survival at 84%, but outcomes varied significantly based on genetic profiles and risk assessments.
- - Systemic CNS prophylaxis was associated with better survival rates, highlighting that while DA-EPOCH-R is effective for certain DEL cases, patients with more
Article Synopsis
- Graft-versus-host disease (GVHD) poses a significant risk following allogeneic stem-cell transplants, and the study examines whether adding antithymocyte globulin (ATG) to posttransplantation cyclophosphamide (PT/CY) can reduce GVHD incidence.
- A retrospective analysis of 268 patients showed that those who received ATG had lower rates of GVHD-related mortality (3% vs. 8%) and a significant difference in overall survival rates at 12 months (79% for ATG vs. 69% for no ATG).
- Despite the promising results in terms of GVHD incidence and survival, multivariate analysis indicated that adding ATG did not significantly impact overall outcomes
Cytokine release syndrome (CRS) represents a life-threatening side effect after haploidentical stem cell transplantation (Haplo-SCT) with posttransplant cyclophosphamide (PT-Cy). Factors predictive of CRS development is still a matter of debate. We retrospectively analyzed 102 consecutive patients receiving a bone marrow (BM) (n = 42) or peripheral blood stem cells (PBSC) (n = 60) Haplo-SCT with PT-Cy.
View Article and Find Full Text PDF